US Propofol market share update

According to IMS, Fresenius Kabi’s market share for Propofol and its equivalent, Diprivan, was 75% in December 2014 (November: 73%). Since March 2014, IMS data on our competition has included direct sales to hospitals. Fresenius Kabi does not report direct sales; our market share is therefore not fully reflected in IMS data.